Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Jun 24;6:28436. doi: 10.1038/srep28436

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016, Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

(A) Primary breast cancer cells showing increased expression of AurkA (KBr2, KBr3, KBr4, bottom panel) exhibited a more aggressive phenotype evaluated as the capacity to generate tumors after injection into immune-compromised mice (top panel), expression of Mmp9, a metastatic marker, and Ki67 high levels (>10%). (B) CD44-positive cells from KBr2, KBr3 and KBr4 showed higher AurkA and wnt3a expression levels in comparison with CD44-negative cells (control), and increased migratory activity evaluated at 24 and 48 hours from seeding (respectively 24 h and 48 h). (C) AurkA knock-down (shAurkA) severely affected AurkA and wnt3a cDNAs levels, adhesion-indipendent growth and migratory activity in KBr2 cells as compared with control cells (empty). Moreover, it reduced levels of AurkA, β–catenin, Wnt3a, Stat3 and Mmp9 proteins.